| Literature DB >> 23533313 |
Sadaf Kasraie1, Thomas Werfel.
Abstract
Atopic dermatitis (AD) is one of the most common and most intensively studied chronic inflammatory skin diseases. Several cofactors, such as an impaired skin barrier function, modifications of the immune system, and a complex genetic background, direct the course of AD. Within this complex network, macrophages play a pivotal role in enhanced susceptibility to cutaneous infections and act as central connecting components in the pathogenesis of AD on the cellular level. In AD, macrophages are known to accumulate in acutely and chronically inflamed skin. During the early and short inflammatory phase, macrophages exert proinflammatory functions like antigen-presenting phagocytosis and the production of inflammatory cytokines and growth factors that facilitate the resolution of inflammation. However, persistence of pro-inflammatory activity and altered function of macrophages result in the development of chronic inflammatory diseases such as AD. The exact mechanism of macrophages activation in these processes is not yet completely understood. Further studies should be performed to clarify the dysregulated mechanism of macrophages activation in AD, and this would allow us to target these cells with versatile functions for therapeutic purpose and improve and control the disease. In this paper, we highlight the new findings on dysregulated function of macrophages and the importance of these cells in the pathogenesis of AD in general and the contribution of these cells in enhanced susceptibility against microbial infections in particular.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23533313 PMCID: PMC3603294 DOI: 10.1155/2013/942375
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Mononuclear phagocyte differentiation in mouse and human. Hematopoiesis in mouse and human begins from the hematopoietic stem cells (HSCs). The HSCs are self-renewing with clonogenic and multipotent features, giving rise to all blood and tissue-resident immune cells. A very small number of HSCs generate immune cells de novo through a multistep differentiation process passing through multilineage progenitors first and to committed progenitors later. All of this process is strictly regulated according to physiological requirements, be it in the steady state or in response to external perturbations, such as infection. Aging also profoundly affects the function of the immune system. The phenomenon is attributable mainly to changes in the HSC compartment that probably gradually reduces its capacity for self-renewal, leading to a progressive reduction in the numbers of immune cells. Myeloid differentiation starts from a common myeloid progenitor (CMP) in the bone marrow. In the mouse, the destiny of CMP is better characterized compared to that of the human counterpart. The CMP generates macrophage-(Mf-) dendritic cell (DC) precursors (MDPs), which are considered the direct progenitor of Gr1+ and Gr1− monocytes in the blood. Besides monocytes, the MDP differentiates into the common DC precursor (CDP), which in turn generates plasmacytoid DC (pDC) and progenitors for conventional DC (pre-cDC). pDC and myeloid DC diverge at the CDP stage. Pre-cDCs migrate out of the BM through the blood circulation into secondary lymphoid tissues (spleen and lymph nodes), where they replenish both CD8+ and CD8− DC in the tissues. In humans, CMPs differentiate to granulocyte-macrophage (CFU-GM) precursor, which give rise to monocytes (CD14hiCD16− and CD14loCD16+) through subsequent differentiation steps, monoblast first, followed by promonocyte. A DC precursor (CFU-DC) derived from CD34+ HSC with unique differentiation potential towards DC has been identified in bone marrow of the mouse, suggesting that a DC progenitor might exist in humans. Blood monocytes (Gr1+ and Gr1− in mouse, CD14hiCD16− and CD14loCD16+ in humans) migrate to nonlymphoid tissues and generate macrophages (Mfs) and interstitial DC (iDC). In the presence of environmental perturbation in vivo or of cytokines in vitro, Gr1+ or Gr1− monocytes in mice and CD16+ or CD16− monocytes in humans differentiate into Langerhans cells (LCs) in the epidermis, as well as inflammatory DC (Inf.DC). LCs are generated by a dermal long-term precursor (pLC) in the steady state. Finally, migratory DC (Mig.DC) moves between nonlymphoid and lymphoid compartments.
Characteristics of monocytes/macrophages-derived cytokines.
| Cytokine | Structure | Size molecular | Receptors | Cell targets | Major functions | Disease association |
|---|---|---|---|---|---|---|
| IL-1 | Heterodimer | 17 kd | IL-1RI, IL-1RII | T cells, fibroblasts, | Induction of | Wide range of autoimmune and inflammatory |
|
| ||||||
| IL-3 | Monomer | 15 kd | IL-3R | Erythroid progenitors, | Hematopoietic growth factor, activation of basophils and eosinophils | Role in allergic diseases for example, AD, different types of cancers, lymphocytic and acute myeloid leukemias |
|
| ||||||
| IL-6 | Homodimer | 19–26 kd | IL-6R, | Hepatocytes, leukocytes, T cells, B cells, hemopoietic cells | Liver: synthesis of acute phase proteins; leukocytes: trafficking, activation; T cell: differentiation, activation, survival; B cell: differentiation, production of IgG, IgM, IgA hematopoiesis | Autoimmune disease, chronic inflammatory |
|
| ||||||
| IL-7 | Monomer | 25 kd | IL-7R and sIL-7R | B, T, and NK | Proliferation of pre-B and pro-B cells (mice), megakaryocytes maturation, VDJ recombinations, naive T-cell survival, | Allergy/autoimmunity |
|
| ||||||
| IL-8 (CXCL8) | Homodimer | 16 kd | CXCR1 and | Neutrophils, NK cells, T cells, basophils, eosinophils, endothelial | Chemoattractant for neutrophils, NK cells, T cells, basophils, eosinophils; mobilization of hematopoieticstem cells; | Increased levels during |
|
| ||||||
| IL-10 | Homodimer | 20.5 kd, predicted | IL-10R1/IL-10R2 | Macrophages, monocytes, T cells, B cells, NK cells, mast cells, DC and | Immune suppression | Cancer, autoimmunity, |
|
| ||||||
| IL-12 | Heterodimer | IL-12a p35, | IL-12Rb1 and | T cells (Th1 cells), | Induce Th1-cell differentiation and | Chronic inflammation (e.g., AD), impaired Th1 response with higher susceptibility |
|
| ||||||
| IL-15 | Monomer | 14-15 kd | IL-15R | T, NK, and NKT cells | Proliferation and activation of NK cells, differentiation of | Autoimmune and inflammatory |
|
| ||||||
| IL-16 | Homotetramer | 56 kd | CD4 | T cells, monocytes, | Chemotaxis, modulation of T-cell response | Increased during various inflammatory and infectious diseases including |
|
| ||||||
| IL-18 | Heterodimer | 22.3 kd | IL-18R | Variety of cells, | Induction of IFN- | Autoimmune diseases |
|
| ||||||
| IL-19 | Monomer | 20.5 kd predicted | IL20R1/IL-20R2 | Keratinocytes | Unknown | Psoriasis |
|
| ||||||
| IL-20 | Monomer | 20 kd predicted size of precursor; 17.5 kd, predicted size of mature protein | IL-20R1/IL-20R2 and IL-22R1/IL-20R2 | Keratinocytes, monocytes | Role in skin biology | Psoriasis, RA, atherosclerosis |
|
| ||||||
| IL-23 | Heterodimer | IL-12b p40, 40 kd; IL-23 p19, 19 kd | IL-12Rb1 and IL-23R | T cells (TH17 cells) | Stimulate production of proinflammatory IL-17 and promote memory T-cell proliferation | Susceptibility to extracellular pathogens, exacerbate organ specific autoimmune inflammation, chronic inflammatory diseases (psoriasis, AD) |
|
| ||||||
| IL-24 | Homodimer and monomer | 23.8 kd, predicted size of unprocessed precursor; 18 kd, unglycosylated | IL20R1/IL-20R2 and IL-22R1/IL-20R2 | Keratinocytes, cancer cells | Tumor suppression | Melanoma, psoriasis |
|
| ||||||
| IL-27 | Heterodimer | IL-27a p28, 28 kd; | WSX-1 and gp130 | T cells, NK cells | Induction of Tbet promoting Th1-cell differentiation, inhibition of Th17-cell response via STAT1 | Immune pathology because of uncontrolled inflammatory response: for example, in psoriasis or in epidermal compartment of |
|
| ||||||
| IL-32 | Unknown | 14.9–26.6 kd | Unknown | Macrophages, DCs, T cells, PBMCs, monocytes | Induction of TNF- | AD, RA, IBD, autoimmune disease |
|
| ||||||
| IL-37 | Unknown | 17–24 kd | IL-18Ra? | Intracellular mechanism manner and DC | Suppression of proinflammatory cytokines and inhibition of DC activation | RA |
|
| ||||||
| TNF- | Homotrimer | 26 kd transmembrane and a 17 kd secreted form | TNF-R1 and TNF-R2 | Both receptors are virtually on all cell types except for the red blood cells, but TNFR1 is more ubiquitous, and TNFR2 is often more abundant on endothelial cells and cells of hematopoietic lineage | Regulation of immune cells: induce fever, apoptotic cell death, (through IL-1 and L-6 production, inhibit tumorigenesis and viral replication, recruiting macrophage and neutrophils to a site of infection | Chronic inflammation (AD, psoriasis, RA, IBD, COPD), Alzheimer's disease, cancer |
AD: atopic dermatitis; AICD: activation-induced cell death; COPD: chronic obstructive pulmonary disease; IBD: inflammatory bowel disease; Ig: immunoglobulin; kd: kilo Dalton; NK: natural killer; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; sIL-6R: soluble interleukin-6 receptor; Th: T helper.